for COQ6 and CYC1 expression. Curves were compared between high (higher than median) vs. low (lower than median). Higher expression of COQ6 was significantly associated with shorter period to metastasis (median survival time, high COQ6 group = 28.9 months, low group = 68.4 months, log rank p = 0.0504. Similarly, higher expression of CYC1 was significantly associated with shorter period to metastasis (median survival time, high CYC1 group = 24.5 months, low group = not reached, log rank p = 0.00434). (D) KM analysis for UM-specific metastasis (n=70) in UM TCGA cohort. Patients with high COQ6 expression (n=35) had significantly shorter period to metastasis than those who have lower expression (n=35) (median survival time, high group = 42.6 months, low group = not reached, log rank p = 0.000334).
Similarly, patients with high CYC1 expression (n=35) had significantly shorter period to metastasis than those who have lower expression (n=35) (median survival time, high group = not reached, low group = not reached, log rank p = 0.00329). (E) KM plots for UM-specific death in UM TCGA cohort (n=77). Patients with high COQ6 expression (n=38) had significantly poorer survival outcome than those who have lower expression (n=39) (median survival time, high group = 41.6 months, low group = not reached, log rank p = 4.24e-05). Likewise, patients with high CYC1 expression (n=38) had significantly poorer survival outcome than those who have lower expression (n=39) (median survival time, high group = 41.6 months, low group = not reached, log rank p = 0.000214). 
